Core Insights - The company achieved positive preclinical study results for Ketamir-2, a novel oral ketamine analog, which were characterized as "highly encouraging" [2][5] - Ketamir-2 demonstrated significant improvements in locomotor activity, travel speed, and reduced anxiety levels in treated mice [2][3] - The company aims to submit an Investigational New Drug (IND) application to the FDA for Ketamir-2 by the end of the year [5] Preclinical Study Results - In the Open Field Test (OFT), mice treated with Ketamir-2 showed reduced swimming distances and speed, indicating an antidepressant effect [8] - The Elevated Plus Maze (EPM) results indicated that Ketamir-2 treated mice spent more time in open arms, suggesting reduced anxiety [3][8] - The Forced Swim Test (FST) revealed significantly reduced immobility times in mice treated with Ketamir-2, highlighting its potential antidepressant properties [4] Company Overview - MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on developing a new synthetic cannabinoid analog for treating neuropathic pain, anxiety, and cognitive decline associated with early-stage dementia [7] - The company has acquired rights to Ketamir, a potential derivative of ketamine, which may have fewer side effects and a faster onset of action compared to existing treatments [7] Market Potential - The positive results from the preclinical studies are expected to validate the potential benefits of Ketamir-2, positioning it as a safer and more effective option for treating depression in home settings [5] - The company is focusing on Ketamir-2 due to its potential for rapid market entry, which could attract significant investor interest [10]
MIRA Announces Positive Test Results